• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

19.68 +0.85 (+4.51%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 09, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2025
From Summit Therapeutics
Via Business Wire
News headline image
Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China
November 07, 2025
From Summit Therapeutics
Via Business Wire
News headline image
Summit Therapeutics to Present at Upcoming Investor Conferences
November 04, 2025
From Summit Therapeutics
Via Business Wire
News headline image
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
October 31, 2025
From Summit Therapeutics
Via Business Wire
News headline image
Summit Therapeutics Raises $500 Million in Private Placement
October 22, 2025
From Summit Therapeutics
Via Business Wire
News headline image
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025
October 20, 2025
From Summit Therapeutics
Via Business Wire
News headline image
Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
October 19, 2025
From Summit Therapeutics
Via Business Wire
News headline image
Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer
October 17, 2025
From Summit Therapeutics
Via Business Wire
News headline image
Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025
October 15, 2025
From Summit Therapeutics
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
September 24, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 24, 2025
From Summit Therapeutics
Via Business Wire
News headline image
HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025
September 24, 2025
From Summit Therapeutics
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
September 14, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
September 10, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC
September 07, 2025
From Summit Therapeutics
Via Business Wire
News headline image
Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025
September 03, 2025
From Summit Therapeutics
Via Business Wire
News headline image
Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025
August 14, 2025
From Summit Therapeutics
Via Business Wire
News headline image
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025
August 11, 2025
From Summit Therapeutics
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.  - SMMT
July 23, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
July 18, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm
July 14, 2025
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT
July 14, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
July 10, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.  - SMMT
July 06, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.  - SMMT
July 01, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
June 30, 2025
Via ACCESS Newswire
News headline image
Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors
June 30, 2025
From Summit Therapeutics Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
June 26, 2025
Via ACCESS Newswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap